We are doing this study to compare the performance of 2 drugs: zanzalintinib and everolimus. We want to know which option is the most effective for treating neuroendocrine tumors.

Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine
Tumors

Adults ages 18+ who:

• Are diagnosed with locally advanced (cannot be removed by surgery) or metastatic (has spread) neuroendocrine tumor
• Have failed to adequately respond to previous treatment

For more information, contact the study team at carolann.wiggs@duke.edu.

If you choose to join the study, you will get a random assignment (like a coin flip) to either take zanzalintinib or everolimus once per day. Both drugs are taken by mouth.

Your study regimen will last for as long as the study doctor believes that you are getting a positive benefit.